补体级联的氧还原调节有助于阿尔茨海默氏症疾病中突触损失
Chang-Ki Oh1, Yubo Wang1, Stuart A Lipton2
1Neurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
概括
由化压力驱动的补充因子的异常S-化,在阿尔茨海默病 (AD) 中病理地激活补充系统. 这导致突触损失和认知衰退,突出了AD病变发生的关键机制.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 神经炎症,以免疫细胞在中枢神经系统 (CNS) 的激活为特征,是阿尔茨海默病 (AD) 发病的核心原因.
- 补体系统是天生的免疫系统的一部分,具有双重的神经保护和神经破坏作用.
- 在AD中补充系统的调节失调有助于突触损失,这是认知能力下降的主要相关因子.
研究的目的:
- 阐明在阿尔茨海默病中补体系统激活的机制.
- 调查化应激和S-化在AD相关的补体失调中的作用.
主要方法:
- 关于神经炎症,补充系统和阿尔茨海默病的最新出版物的审查.
- 对反应性物种 (RNS) 和氧化 (NO) 相关物种的作用的分析.
- 检查氧化还原介导的翻译后修饰,特别是S-化.
主要成果:
- 异常的补充因子S-化被确定为控制AD补充级联的关键机制.
- 与过度RNS生成相关的化应激,支持这种异常的S-化.
- 由S-基化补充蛋白驱动的病理补充激活,有助于AD中的突触损失.
结论:
- 异常的NO相关物种对补充蛋白的S-化是AD中补充系统过度激活的关键驱动因素.
- 这种病理补充激活直接导致突触损失和阿尔茨海默病的认知障碍.
- 了解这种氧化还原介导机制为AD的病变产生提供了新的见解.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Role of Neurotransmitters in Memory
992
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
992
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Complement System
2.7K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.7K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
208
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
208


